Researchers reported that independent transcription start sites regulate isoform diversity of RBM20, shaping splicing programs in health. The study highlights how RNA-binding protein regulation can occur at the level of transcript architecture, influencing downstream splice site selection. By characterizing how distinct start sites contribute to RBM20 isoform output, the work provides a mechanistic route to understand splicing variability across biological contexts. RBM20 is implicated in multiple gene expression and disease pathways, and isoform control could help explain phenotype differences that are not captured by total RBM20 expression alone. The findings may enable more precise therapeutic targeting strategies—either by modulating RBM20 isoform balance or by accounting for isoform-dependent splicing effects in disease models.